Teva Pharmaceutical IndustriesTEVA
Recorded

Teva Pharmaceutical Industries 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration1 hr 9 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello everybody, welcome to the Q2 2026 Teva Pharmaceutical Industries earnings conference call. My name is Elliot. I'll be coordinating your call today. If you would like to ask a question during today's event, please press star followed by one on your telephone keypad. I would now like to hand over to Christopher Stevo. Please go ahead. Thank you, Elliot.

Chris StevoSenior VP of Investors Relation and Competitive Intelligence

Good morning and good afternoon, everyone. Thank you for joining us on our second quarter call. Obviously, our materials are posted to our website this morning, so please see those. Before I turn the call over to our CEO, Richard Francis, I'd like to remind everyone that we'll be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, we undertake no obligation to update these statements subsequently. With that, Richard Francis. Thanks, Chris.

Richard FrancisCEO

Good morning and good afternoon, everybody. Thank you for joining the call today. Joining me on the call today will be Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer, and Eli Kalif, our Chief Financial Officer. Now moving on to the slide I always start with, the Pivot to Growth slide, our strategy that we launched in 2023 that's based on these four pillars. We'll summarize how we've performed against these four pillars in quarter two. Just to give you a quick overview. On deliver on our growth engines, AUSTEDO, AJOVY, and UZEDY all delivered strong Q2 performance, we are raising our full-year revenue guidance for these products. It's worth reminding you that the innovative portfolio is reshaping our financial profile with stronger revenue growth, margins, and free cash flow.

Richard FrancisCEO

As we move on to the second pillar to step up innovation on pipeline, this year will provide eight major milestones. This now includes ecopipam, this gives us the potential for five submissions over the next five years. With regard to creating a generics powerhouse, biosimilars are becoming a growth platform within generics. We now have 15 products in the market and 14 in our pipeline, we see additional opportunities through further partnerships. On our final pillar, focus the business, I think we made great progress on our capital allocation. We've had one of the agencies upgrade us, Fitch, to investment grade, we see the other two doing this in the not-too-distant future. We also allocated capital to the acquisition of Emalex. We closed that deal in June, we're expecting to launch next year if FDA approves.

Richard FrancisCEO

Finally, the conversion of the ADSs to ordinary shares and the ability to list on the New York Stock Exchange should make investing in Teva accessible to more investors. Moving on to the financials. I'm really proud of this slide, and you may ask why, but let me walk you through why. We have stable revenues, despite nearly 8% of headwinds from generic REVLIMID last year-over-year. We're growing our profit margin as well, 80 basis points, improving gross margins year-over-year, driven by strong innovative growth despite this loss of generic REVLIMID. We're actually growing our EBITDA, obviously excluding the Emalex acquisition. Our free cash flow is up 31% as a result of our disciplined capital allocation. If I go on to the next slide, I'll give you a bit more detail.

Richard FrancisCEO

As you can see, the innovative portfolio has had a strong quarter, up 43% year-on-year. UZEDY up 40%, UZEDY up 43%, AJOVY up 56%. Generics is down 15%, this is largely due to lower generic REVLIMID contribution versus 2025. If I now go into a bit more detail, starting with AUSTEDO, a core growth driver here. This is another strong quarter. In the U.S., revenue reached $676 million, up 33% year-over-year, global revenue up 40%. Demand remains strong with TRx up 14% and milligram growth up 21%, supported by new patient starts and adherence. AUSTEDO XR now represents over 60% of new patients, strengthening convenience, adherence, long-term durability. Because of this strong quarter, we're now increasing our outlook by $50 million at the midpoint, so it's now $2.45 billion-$2.6 billion.

Richard FrancisCEO

It's worth noting that the midpoint there is $2.5 billion, which was the target we gave ourselves for 2027, so we have a chance of beating this a year early. I think more importantly, we see continued momentum and a significant untreated population that still could benefit from AUSTEDO, hence our confidence in greater than $3 billion of peak sales. Moving on to UZEDY. UZEDY continues to grow with strong momentum. It is the fastest-growing long-acting injectable treatment for schizophrenia amongst atypical LAIs. Revenue grew 43% to $77 million in Q2 based on strong demand. That was reflected in our TRx and MOT up 63% year-over-year. The commercial execution has been impressive, this can be seen with UZEDY nearly doubling the risperidone long-acting share, it has now gone from 5% to nearly 10%.

Richard FrancisCEO

UZEDY's capturing nearly 80% of the risperidone LAI market. Because of this strong performance, we're increasing the outlook by $15 million at the midpoint, so the new guidance is $270 million-$290 million. This continued excellent execution has given us great confidence in the upcoming launch of olanzapine, which I'll now move on to. Olanzapine represents a meaningful next growth opportunity with FDA action and U.S. launch anticipated in Q4 of this year. The unmet medical need is significant. Olanzapine holds roughly 20% of U.S. oral prescriptions, while olanzapine LAI use is less than 1% of the LAI market. We know this market. We can really leverage the synergies with UZEDY, also the deep knowledge of the schizophrenia market, whether that's physicians, patients, nurse practitioners, or some of the long-term care facilities.

Richard FrancisCEO

Our direction of travel is clear, to deliver a best-in-class launch that expands treatment options and reinforces our leadership in the LAIs. Olanzapine, together with UZEDY, gives us a compelling path to expected peak sales of $1.5 billion to $2 billion of revenue. Moving on to AJOVY. AJOVY demonstrates our ability to execute in competitive, innovative markets wherever they may be. We continue to outpace the injectable market growth, and we lead in many of the markets despite entering late. Q2 global revenue reached $244 million, up 56% year-over-year. The U.S. revenue grew 83%, driven by improved contracting, favorable gross to net, and market share gains. Ex-U.S. momentum remains strong, supported by volume growth and leading brand shares across Europe and international markets. Because of this strong quarter, we're increasing our outlook by $90 million at the midpoint. Now the range is $850 million to $870 million.

Richard FrancisCEO

Looking beyond 2026, we see a clear path to $1 billion peak sales for AJOVY. Moving on to the newest member of the innovative family, ecopipam, a first-in-class opportunity with compelling efficacy and favorable tolerability in Tourette syndrome, a serious pediatric neurological disorder with limited treatment options. We've already filed with the FDA with a potential launch in the first half of 2027. The unmet medical need is clear. There are 100,000 pediatric patients who live with Tourette syndrome. Only 50,000 are treated, and only 20%-30% remain on therapy after one year. This shows there is a real need for a product like ecopipam with compelling efficacy and favorable tolerability. We're well positioned to execute on this, leveraging our CNS capabilities and the experience we've garnered with AUSTEDO, UZEDY, and soon to be long-acting olanzapine.

Richard FrancisCEO

This moves on to a slide which I've never been able to show before, actually, in my rather long career. I apologize for the small font, but we had to get everything on one slide. What this highlights is just the innovative pipeline we have and our potential to launch one asset per year for the next five years, transforming Teva into a leading biopharma company. The near-term launches are clearly sequenced. Olanzapine in 2026, ecopipam in 2027, followed by DARI, emricasan, and duvakitug through 2028 to 2030. Obviously, all subject to regulatory approvals. Looking up to 2035, we see further upside from the additional indications that we've announced there for duvakitug, as well as the additional indication of anti-IL-15, as well as our TSLP/IL-13. We also are pursuing more business opportunities as well. Business development opportunities, that is.

Richard FrancisCEO

Moving into our pipeline slide. I'll try and be short on this and allow Eric to talk more through this, but there are some points which I think are worth mentioning. One is this is a near-term pipeline with many catalysts, as I mentioned in my opening remarks. We've got anti-IL-15. We saw the vitiligo data. We're going to see the select data in the second half of the year. We've got these near-term launches with olanzapine and ecopipam filed. DARI is progressing well. We've announced two new indications for duvakitug. Together, all these assets represent over $10 billion of peak sales. I have realized we said that before, and that was prior to actually adding ecopipam to this slide, as well as the two new indications of duvakitug, I must remember to update it. What does this all do for Teva?

Richard FrancisCEO

It fundamentally transforms our growth profile. Our growth is really accelerating with revenue moving from $4.9 billion in 2022 to an expected $16.5-$16.8 this year. Our portfolio is shifting towards higher value innovation, with innovative revenue expected to reach 22% of total revenue in 2026, up from 9%. You can see where it is heading to 2030. With regards to margins, we are creating stronger margins, with gross margins expected to expand from 54% to more than 60% by 2030+. This is once again fueled by our innovative portfolio. Moving on to our generics business. Generics business is down 15% versus Q2 2025, but I don't think that tells the full story. If you exclude generic Revlimid, our generic business remains stable.

Richard FrancisCEO

Global generics was down 2%, the U.S. up 1%. Our ex-U.S. decrease mainly was due to lower product launches this year and a softer cough and cold season. 2026 is expected to be somewhat softer, we can continue to see a stable generics business capable of delivering 1%-2% annual growth over the long term, supported by a steady flow of our new product launches. I remain very excited about the future of our generics business. One of the main reasons I am confident is the growth rate that is starting to emerge from our biosimilar portfolio and pipeline. Let me move on to this now. Biosimilars are transforming our generics portfolio. Before Pivot to Growth, we had three biosimilars. Today, we have 15 in the market, and in the next few years, we expect to double it.

Richard FrancisCEO

It is not just the size of our portfolio, it is the execution. In the U.S., two out of our five products are ranked number one. A third is neck and neck, and I believe soon to become a number one. In the EU, where we have just launched three biosimilars, early signs are very positive. We continue to seek partnering to increase this portfolio. I believe we are becoming the partner of choice because of this excellent execution. Based on our current momentum, we are on track to exceeding our $800 million by 2027. To conclude, before I hand over to Eric, we are on track to hit our 2027 financial growth targets of mid-single revenue growth, non-GAAP operating income target of 30%. A net debt EBITDA below 2%, and cash converse earnings of 80%. With that, I will hand over to Eric.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day